Key facts: AstraZeneca has secured a deal worth up to $555 million with Algen Biotechnologies for exclusive rights to develop therapies using Crispr technology and AI for immune disorders.
Less than 1 min read
- AstraZeneca has secured a deal worth up to $555 million with Algen Biotechnologies for exclusive rights to develop therapies using Crispr technology and AI for immune disorders.1
- AstraZeneca's stock rose to 12,726.00 pence, up 76.00 pence (0.60%), and closed at 1,611.00 SEK in Sweden, gaining 23.00 SEK (1.45%).2
- AstraZeneca has teamed up with Quell Therapeutics to create treatments for inflammatory bowel disease, emphasizing research on regulatory T cells, a key area in immune system regulation.3